Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00287729 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT00287729 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 344 participants.
The verdict
NCT00287729, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.
Interventions
- DRUG Placebo
- DRUG Pirfenidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00287729
The ClinicalTrials.gov registry entry for NCT00287729 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00287729 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00287729 about?
NCT00287729 is a clinical study titled "Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis". The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with ...
What is the current status of trial NCT00287729?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2006-04. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00287729?
The interventions under investigation include: Placebo (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT00287729?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.